Breaking News Instant updates and real-time market news.

CAR

Avis Budget

$29.35

-0.23 (-0.78%)

, SRCI

SRC Energy

$4.59

0.12 (2.68%)

19:02
02/20/19
02/20
19:02
02/20/19
19:02

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Avis Budget (CAR) up 9.7%... SRC Energy (SRCI) up 9.2%... Albemarle (ALB) up 6.8%... Coeur Mining (CDE) up 5.4%... Pegasystems (PEGA) up 4.3%... Jack in the Box (JACK) up 3.4%... Boston Beer (SAM) up 3.2%... Genomic Health (GHDX) up 2.8%... NetEase (NTES) up 2.3%... Grand Canyon Education (LOPE) up 1.9%... Synopsys (SNPS) up 1.9%... Energy Transfer (ET) up 1.6%... Cheesecake Factory (CAKE) up 1.3%... Noble Corp (NE) up 1.2%... ALSO HIGHER: Foot Locker (FL) up 1.1% after new $1.2B stock buyback and raised dividend. DOWN AFTER EARNINGS: Carbon Black (CBLK) down 18.5%... SpartanNash (SPTN) down 9.1%... Vipshop Holdings (VIPS) down 7.8%... Flowserve (FLS) down 7.3%... Evertec (EVTC) down 6.3%... CyrusOne (CONE) down 5.7%... Cimarex (XEC) down 3.2%... Xperi Corp (XPER) down 2.7%... SM Energy (SM) down 2.5%... Agilent (A) down 2.3%... Impinj (PI) down 2.1%... QEP Resources (QEP) down 1.8%... NuVasive (NUVA) down 1.7%... Icon Public (ICLR) down 1.7%... Ribbon Communications (RBBN) down 1.3%... Nordson (NDSN) down 1.3%... SolarEdge (SEDG) down 1.2%. Movers as of 18:30ET.

CAR

Avis Budget

$29.35

-0.23 (-0.78%)

SRCI

SRC Energy

$4.59

0.12 (2.68%)

ALB

Albemarle

$82.82

-0.305 (-0.37%)

CDE

Coeur Mining

$5.55

0.045 (0.82%)

PEGA

Pegasystems

$59.39

0.95 (1.63%)

JACK

Jack in the Box

$78.95

-2 (-2.47%)

SAM

Boston Beer

$267.95

-0.97 (-0.36%)

GHDX

Genomic Health

$83.70

1.11 (1.34%)

NTES

NetEase

$232.66

3.11 (1.35%)

LOPE

Grand Canyon

$97.13

0.18 (0.19%)

SNPS

Synopsys

$102.98

1.08 (1.06%)

ET

Energy Transfer LP

$15.51

-0.13 (-0.83%)

CAKE

Cheesecake Factory

$46.42

-0.07 (-0.15%)

NE

Noble Corp.

$3.32

0.17 (5.40%)

FL

Foot Locker

$60.00

0.12 (0.20%)

CBLK

Carbon Black

$16.47

0.13 (0.80%)

SPTN

SpartanNash

$21.98

-0.25 (-1.12%)

VIPS

Vipshop

$7.30

0.35 (5.04%)

FLS

Flowserve

$47.75

0.485 (1.03%)

EVTC

Evertec

$30.65

0.3 (0.99%)

CONE

CyrusOne

$57.19

-0.46 (-0.80%)

XEC

Cimarex Energy

$76.38

1.3 (1.73%)

XPER

Xperi

$23.18

0.36 (1.58%)

SM

SM Energy

$19.70

0.61 (3.20%)

A

Agilent

$78.56

1.08 (1.39%)

PI

Impinj

$19.30

1.39 (7.76%)

QEP

QEP Resources

$8.19

-0.08 (-0.97%)

NUVA

NuVasive

$55.47

-1.81 (-3.16%)

ICLR

Icon

$145.61

0.28 (0.19%)

NDSN

Nordson

$138.81

-0.42 (-0.30%)

SEDG

SolarEdge

$41.48

-1.87 (-4.31%)

RBBN

Ribbon Communications

$6.06

-0.08 (-1.30%)

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 04

    Mar

  • 04

    Mar

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 06

    Mar

  • 06

    Mar

  • 11

    Mar

  • 13

    Mar

  • 13

    Mar

  • 20

    Mar

  • 21

    Mar

  • 27

    Mar

  • 28

    Mar

  • 22

    May

  • 18

    Jun

  • 16

    Jul

  • 17

    Jul

  • 26

    Sep

  • 27

    Sep

CAR Avis Budget
$29.35

-0.23 (-0.78%)

10/16/18
10/16/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. NEEDHAM SAYS BUY TAPESTRY: Needham analyst Rick Patel upgraded Tapestry to Buy from Hold and kept his $50 price target. The analyst notes that after a 14% selloff in the stock price driven by tariff-related concerns and the slowdown of Asia sales at LVMH, the risk-reward is favorable. Patel estimates that the hit to EPS from the impact of the handbag tariff should be "relatively modest" at about 1%. The analyst further notes that Tapestry has "ample white space" for long term growth in China through new distribution, while its North America sales indicate "well-controlled promotions" for Coach and Kate Spade. ANALYSTS SAY BUY FACEBOOK IN NEW INITIATIONS: Loop Capital analyst Alan Gould initiated Facebook with a Buy rating and a price target of $210, saying the stock is valued "quite attractively" after a "strong year financially and a challenging year operationally". The analyst also notes that the company's guidance is likely "conservative" given the company's propensity to beat consensus estimates. Meanwhile, Rosenblatt analyst Mark Zgutowicz started Facebook with a Buy rating in a note partially entitled "Facebook: Value, Not Trap." Given the stock's current valuation, there appears to be little confidence consensus expectations will be met and he is "in that camp," forecasting calendar 2019 EPS that is about 8% below consensus, Zgutowicz tells investors. However, with that said, he sees the anticipated EPS shortfall as priced in the shares and would be a buyer of the stock in front of the Q3 report, stating that he sees a bottoming for News Feed fatigue and enough light ahead with new product innovation and Instagram and Watch optionality. Zgutowicz set a $213 price target on Facebook shares. TILRAY TARGET SET AT $200 AS CANADA GETS READY TO LEGALIZE: Benchmark analyst Mike Hickey initiated coverage of Tilray with a Buy rating and $200 price target, citing its early leadership in the medical cannabis market in Canada and the upcoming legalization of recreational cannabis, which begins in the North American nation tomorrow. He believes the company's strategic alliance with Novartis (NVS) and supply agreements with Canadian pharmacies that give Tilray a competitive edge in the Canadian medical cannabis market, Hickey tells investors. He also believes the potential international opportunity is "enormous," estimating that the global cannabis market opportunity could exceed $200B over the long-term. JEFFERIES SEES NO COMPETING BIDS FOR PINNACLE: Jefferies analyst Akshay Jagdale downgraded Pinnacle Foods (PF) to Hold from Buy and lowered his price target for the shares to $68 from $72. The analyst assumes Conagra Brands' (CAG) bid to buy the company for $68 will go through without any competing bids. The stock should trade in line with its $68 transaction price until completion of the deal, Jagdale tells investors. GOLDMAN PREDICTS AVIS, HERTZ OUTLOOKS WILL DISAPPOINT: Goldman Sachs analyst David Tamberrino nudged the price target on Avis Budget (CAR) lower to $30 from $31 while keeping the price target on Hertz at $13 as part of his broader research note previewing Q3 results for the two Sell-rated U.S. car rental names. The analyst notes that Hertz (HTZ) may top Q3 consensus earnings and Avis Budget could miss based on his analysis of their respective pricing trends and residual values, but both have an added risk from reduced airport volume growth amid tightening competition among the ride hailing operators like Uber and Lyft. Tamberrino expects the car rental industry to remain challenged overall, noting that positive pricing will not be sustained, residual values will be pressured as more cars come off lease, and rising interest rates exert pressure on their balance sheets' high debt levels.
12/06/18
LSCM
12/06/18
NO CHANGE
LSCM
I.D. Systems expansion with Avis provides multiple benefits, says Lake Street
Lake Street analyst Jaeson Schmidt reiterated a Buy rating and $9.50 price target on I.D. Systems (IDSY) after the company expanded its relationship with Avis (CAR) with a new 75K unit order. Schmidt believes the expansion has three key benefits for I.D. Systems -- It should be additive to the P&L as he estimates its value at over $30M, it was not a one-off order and he would not be surprised if the relationship was further expanded, and concerns on tough year-over-year comparisons should lessen.
02/11/19
GSCO
02/11/19
UPGRADE
Target $35
GSCO
Buy
Avis Budget upgraded to Buy from Sell at Goldman Sachs
Goldman Sachs analyst David Tamberrino double upgraded Avis Budget (CAR) to Buy from Sell and raised his price target for the shares to $35 from $30. The analyst also maintains a Sell rating on Hertz (HTZ). Trading at 6.2 times estimated 2019 EBITDA versus a historical trough multiple of 5.9 times and long-term average 8.4 times, shares of Avis look attractive for mean reversion, Tamberrino tells investors in a research note. The analyst believes most of the headwinds the industry is facing appear priced in at current share levels. Further, he views Avis as better positioned than Hertz and thinks it should be able to improve results through cost optimization strategies in 2019 and beyond.
02/11/19
02/11/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Buy from Hold at Canaccord with analyst Jed Dorsheimer saying he thinks electric vehicle, or EV, penetration is underappreciated by Wall Street. 2. Avis Budget (CAR) upgraded to Buy from Sell at Goldman Sachs with analyst David Tamberrino saying trading at 6.2 times estimated 2019 EBITDA versus a historical trough multiple of 5.9 times and long-term average 8.4 times, shares of Avis look attractive for mean reversion. 3. Electronic Arts (EA) upgraded to Buy from Neutral at BofA/Merrill with analyst Justin Post citing the surprise start to Apex Legends' new Battle Royale. 4. Hasbro (HAS) upgraded to Buy from Neutral at Monness Crespi. 5. Lloyds Banking (LYG) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SRCI SRC Energy
$4.59

0.12 (2.68%)

12/07/18
JPMS
12/07/18
DOWNGRADE
Target $6
JPMS
Neutral
SRC Energy downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Glick downgraded SRC Energy (SRCI) to Neutral and lowered his price target for the shares to $6 from $9. The analyst ranks SRC second to PDC Energy (PDCE) within the Wattenberg, but prefers PDC's ability to re-allocate capital to the Delaware in the event Colorado's soon to be heavily Democratic government works to enact legislation that limits the oil and gas industry.
01/29/19
RHCO
01/29/19
NO CHANGE
RHCO
SunTrust lowers price targets on Energy E&P names on continued oil volatility
SunTrust analyst Welles Fitzpatrick has lowered his price target on select energy exploration and production companies as part of his broader sector note, citing rig count declines, volatile oil prices, and low visibility from delayed 2019 guidance to Q4 earnings. The analyst lowers the price target on Noble Energy (NBL) to $32 from $42 and Extraction Oil & Gas (XOG) to $10 from $22, adding that along with Range Resources (RRC), these companies are "candidates for deceleration". Fitzpatrick also lowered his price target on Anadarko Petroleum (APC) to $55 from $70, HighPoint Resources (HPR) to $5 from $8, SRC Energy (SRCI) to $9 from $14, and PDC Energy (PDCE) to $57 from $65.
02/07/19
BMOC
02/07/19
NO CHANGE
Target $7
BMOC
Market Perform
SRC Energy price target lowered to $7 from $10 at BMO Capital
BMO Capital analyst Philip Jungwirth lowered his price target on SRC Energy to $7 and kept his Market Perform rating. The analyst says the company posted a "significantly" higher Q4 output but on higher capital expenditure, while its outlook for FY19 spending was also lowered by 28% from last year. With flat production guidance for FY19, Jungwirth sees SRC Energy's EBITDAX down 3% in FY19 and 17% in FY20 from his prior estimates.
02/07/19
IFSG
02/07/19
UPGRADE
IFSG
Outperform
SRC Energy upgraded to Outperform from Market Perform at IFS Securities
ALB Albemarle
$82.82

-0.305 (-0.37%)

01/18/19
LOOP
01/18/19
NO CHANGE
Target $112
LOOP
Buy
Albemarle price target lowered to $112 from $128 at Loop Capital
Loop Capital analyst Chris Kapsch lowered his price target on Albemarle to $112 to reflect investors' sentiment turning more cautious on the debate whether lithium is a "commodity or specialty". The analyst also keeps his Buy rating on the shares and recommends that investors buy at current levels given the sharp pullback in the stock price. Kapsch contends that the implied valuation on the lithium franchise is too low, anticipating higher lithium prices this year.
01/29/19
JEFF
01/29/19
NO CHANGE
Target $150
JEFF
Buy
Albemarle valuation attractive after recent pullback, says Jefferies
The recent selloff has brought Albemarle to levels that imply its new lithium platform, if anything, is as bad as the bromine platform a few years ago, Jefferies analyst Laurence Alexander tells investors in a research note titled "Trading As If Li Has No Tomorrow, Or At Least Worse Than Br Was." Triggers for a share rally range from stabilization in lithium benchmarks to confirmation customer requirements help longer term contracts remain resilient even when auto manufacturers are curtailing activity, adds the analyst. He finds Albemarle's relative multiple as historically attractive and keeps a Buy rating on the shares with a $150 price target.
02/05/19
SBSH
02/05/19
DOWNGRADE
SBSH
Neutral
Albemarle downgraded to Neutral from Buy at Citi
Citi analyst P.J. Juvekar downgraded Albemarle to Neutral.
02/05/19
SBSH
02/05/19
DOWNGRADE
SBSH
Neutral
Citi downgrades Albemarle to Hold, prefers Livent for lithium exposure
Citi analyst P.J. Juvekar downgraded Albemarle (ALB) to Neutral from Buy and lowered his price target for the shares to $81 from $90. The stock closed yesterday up 64c to $81.94. The analyst recommends Livent (LTHM) for investors seeking lithium exposure. Slower industrial activity and weak refining margins increases downside risks to Albemarle's Bromine and Catalysts divisions, Juvekar tells investors in a research note. He sees Bromine and Catalyst EBITDA declining through 2019. Livent should outperform Albemarle after FMC (FMC) spins its Livent stake to shareholders, says Juvekar. He points out that hydroxide, which Livent has more exposure to, is growing faster than carbonate. The analyst sees less downside risk to hydroxide prices than carbonate over the next couple of years "as the former has more tenable barriers to entry and higher concentration of competitors." Further, Albemarle has limited balance sheet flexibility following the Mineral Resources deal, which exposes it to upstream commodity risk for a few years before conversion capacity starts up, Juvekar contends.
CDE Coeur Mining
$5.55

0.045 (0.82%)

04/27/18
ROTH
04/27/18
DOWNGRADE
Target $9
ROTH
Neutral
Coeur Mining downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Joe Reagor downgraded Coeur Mining to Neutral and lowered his price target for the shares to $9 from $11. A deeper dive into the better than expected Q1 results showed higher than expected costs at most of the company's mines, Reagor tells investors in a research note. In addition, the analyst revised his long-term silver price forecast as the commodity has continued to lag gold.
07/10/18
ROTH
07/10/18
UPGRADE
Target $9
ROTH
Buy
Coeur Mining upgraded to Buy from Neutral at Roth Capital
Roth Capital analyst Joe Reagor upgraded Coeur Mining to Buy from Neutral, with a $9 price target, as another "strong" quarter at Palmarejo leads to increased guidance.
07/31/18
NBLE
07/31/18
UPGRADE
NBLE
Buy
Coeur Mining upgraded earlier to Buy from Hold at Noble Financial
10/10/18
BMOC
10/10/18
NO CHANGE
Target $8
BMOC
Outperform
Coeur Mining price target lowered to $8 at BMO Capital on 'weak' Q3 production
BMO Capital analyst Ryan Thompson lowered his price target on Coeur Mining to $8 from $10.50, saying that shares could come under pressure following "weak" Q3 production results as well as the reported "slippage" on the timeing of Silvertip permit amendment. While the analyst keeps his Outperform rating, he states that Q4 output will have to be strong across the company's portfolio for it to achieve its production targets. Thompson also expects Coeur Mining's FY19 output to be "significantly stronger" as Silvertip continues to ramp up.
PEGA Pegasystems
$59.39

0.95 (1.63%)

04/26/18
04/26/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Omega Healthcare (OHI) initiated with a Market Perform at Raymond James. 2. HighPoint Resources (HPR) initiated with an Overweight at JPMorgan. 3. Veritone (VERI) initiated with a Buy at DA Davidson. 4. Pegasystems (PEGA) initiated with a Buy at DA Davidson. 5. Apollo Medical (AMEH) initiated with a Buy at Dougherty. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/15/18
MUFG
08/15/18
NO CHANGE
Target $65
MUFG
Overweight
Pegasystems headline shortfalls due to higher subscription mix, MUFG says
MUFG analyst Stephen Bersey kept his Overweight rating and $65 price target on Pegasystems after its Q2 results, saying that despite the headline miss, the company had a solid quarter. The analyst states the reported shortfalls were due to a "higher subscription mix than either the company or the Street anticipated", adding that looking through the lens of annual contract value", the growth of 31% was "impressive". Bersey adds that Pegasystems is maintaining its operating momentum.
11/07/18
MUFG
11/07/18
NO CHANGE
Target $55
MUFG
Overweight
Pegasystems earnings miss due to 'elevated subscription mix', says MUFG
MUFG analyst Stephen Bersey kept his Overweight rating and $55 price target on Pegasystems after its Q3 results, saying the EPS miss was due to "an elevated subscription mix" which dampens near term revenues. The analyst believes that the company is still seeing a "healthy demand for its offerings" and has already started to "benefit from its revenue model transition".
01/03/19
BNCH
01/03/19
NO CHANGE
BNCH
Activision, Canopy Growth among Best Ideas for first half of 2019 at Benchmark
Benchmark analysts selected their Best Ideas for the first half of 2019, naming 16 stocks, including: Activision Blizzard (ATVI), BioTelemetry (BEAT), Biofrontera (BFRA), Ctrip (CTRP), Huazhu Group (HTHT), II-VI (IIVI), Intevac (IVAC), LHC Group (LHCG), Meredith (MDP), Marvell (MRVL), NeoGenomics (NEO), Pegasystems (PEGA), Silicon Labs (SLAB), Varonis (VRNS), Canopy Growth (CGC) and Waitr Holdings (WTRH).
JACK Jack in the Box
$78.95

-2 (-2.47%)

11/29/18
BARD
11/29/18
NO CHANGE
Target $98
BARD
Outperform
Jack in the Box could be worth $115 per share in buyout scenario, says Baird
After Reuters reported earlier today that Jack in the Box (JACK) is exploring options that could include a sale of the company, Baird analyst David Tarantino said he would not rule out the possibility of a sale and "at a minimum" the speculation should help put a floor under the stock in the short run. He sees Sonic (SONC), which has agreed to be bought by Inspire Brands, as the closest comparable to Jack in the Box. The analyst noted that at a similar EBITDA multiple as Inspire agreed to pay, Jack would be worth roughly $115 per share. Tarantino has an Outperform rating on Jack in the Box with a $98 price target.
11/30/18
WEDB
11/30/18
NO CHANGE
Target $85
WEDB
Neutral
Jack in the Box 'largely fully valued' at current levels, says Wedbush
Following a Reuters report that Jack in the Box (JACK) is exploring a sale, Wedbush analyst Nick Setyan says he does not expect any offers to approach Sonic's (SONC) multiple, telling investors in a research note that he believes Jack in the Box, at current levels, is largely fully valued. He maintains a Neutral rating and $85 price target.
11/30/18
JEFF
11/30/18
NO CHANGE
Target $95
JEFF
Hold
Jefferies views buyout of Jack in the Box as unlikely
While a buyout of Jack in the Box (JACK) is possible after Reuters reported yesterday that the chain is exploring options that could include a sale, such a transaction is not likely, Jefferies analyst Alexander Slagle tells investors in a research note. The analyst thinks Sonic (SONC) could be viewed as the closest comp to Jack in Box but he doesn't believe a transaction is likely for the latter given fewer potential synergies and less room for multiple expansion versus current share levels. He adds, however, that the multiple paid by Inspire Brands for Sonic implies a $110 per share value for Jack in the Box. Slagle maintains a Hold rating on the shares with a $95 price target. Many of the biggest opportunities for value creation at Jack in the Box have already been executed or are now well-underway, including refranchising, sale of non-core brands and costs reductions, says the analyst. The stock closed yesterday at $88.54.
12/18/18
OPCO
12/18/18
NO CHANGE
Target $92
OPCO
Outperform
Probability of Jack in the Box deal 'much higher' than 30%, says Oppenheimer
Oppenheimer analyst Brian Bittner notes that Jack in the Box confirmed its pursuit of strategic alternatives, including a possible sale, and argues that the investment opportunity in shares has become binary. Either the company gets sold at a range he estimates to be $90-$110/share, or it fails to be acquired and downside exists to mid-$70s range, Bittner contends. The analyst believes current share price of $82 suggests investors are only placing a 30% probability of a deal occurring, but he believes probability is much higher as private equity likely sees strategic value in Jack in the Box's above-average unit-economics, robust steady-state free cash flow power and ability to execute a bolder operating plan as a private company. Bittner reiterates an Outperform rating and $92 price target on the shares.
SAM Boston Beer
$267.95

-0.97 (-0.36%)

09/13/18
GUGG
09/13/18
INITIATION
GUGG
Buy
Boston Beer initiated with a Buy at Guggenheim
09/14/18
GUGG
09/14/18
INITIATION
Target $381
GUGG
Buy
Boston Beer initiated with a Buy on top-line growth at Guggenheim
Guggenheim analyst Laurent Grandet initiated Boston Beer with a Buy and $381 price target saying he expects FY19/FY20 growth 6%/8% above consensus driven by key innovations and a recovery from the Samuel Adams franchise.
12/13/18
UBSW
12/13/18
INITIATION
Target $228
UBSW
Sell
Boston Beer initiated with a Sell at UBS
UBS analyst Sean King started Boston Beer with a Sell rating and $228 price target. The analyst views the stock as expensive and expects a "meaningful growth" deceleration in the near-term.
12/13/18
12/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alibaba (BABA) assumed with a Buy at Mizuho. 2. Molson Coors (TAP) and Keurig Dr Pepper (KDP) were initiated with a Buy at UBS, while PepsiCo (PEP) and Constellation Brands (STZ) were initiated with a Neutral, and Monster Beverage (MNST) and Boston Beer (SAM) were initiated with a Sell. 3. SeaSpine (SPNE) initiated with an Outperform at Wells Fargo. 4. XPO Logistics (XPO) initiated with a Buy at SunTrust. 5. Enanta (ENTA) initiated with a Hold at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
GHDX Genomic Health
$83.70

1.11 (1.34%)

11/07/18
ADAM
11/07/18
NO CHANGE
Target $82
ADAM
Buy
Genomic Health price target raised to $82 from $70 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Genomic Health to $82 from $70 following its beat and raise Q3 results. The analyst cited its topline growth and raised top and bottom line outlook for the year. Massaro reiterated his Buy rating on Genomic Health shares.
11/28/18
PIPR
11/28/18
NO CHANGE
PIPR
Piper sees 'incremental winners' in final Clinical Laboratory Fee Schedule
CareDx (CDNA), Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA) and Quest Diagnostics (DGX) are the "incremental winners" in the 2019 Final Clinical Laboratory Fee Schedule determinations announced by the Centers for Medicare and Medicaid Services, Piper Jaffray analyst William Quirk tells investors in a research note. Specifically, CMS priced the advanced carrier screening panel at $2,449 versus the code stack method yesterday, Quirk writes. He points out that Genomic Health gets a bump for a couple tests and CareDx competitor TAI Diagnostics ends up with a likely longer pathway to reimbursement.
12/19/18
OPCO
12/19/18
INITIATION
OPCO
Perform
Genomic Health initiated with a Perform at Oppenheimer
Oppenheimer analyst Kevin DeGeeter started Genomic Health with a Perform rating. The analyst views Genomic Health as a leader in diagnostic testing for predicting response to certain therapeutics and for staging of oncology patients. However, given the strong share price appreciation since presentation of TAILORx data, DeGeeter believes the stock is fully valued.
01/02/19
NEED
01/02/19
INITIATION
Target $86
NEED
Strong Buy
Genomic Health initiated with a Strong Buy at Needham
Needham analyst Stephen Unger initiated Genomic Health with a Strong Buy rating and $86 price target, stating that he sees significant EPS upside potential from the commercialization of its expanding portfolio of molecular diagnostic testing services and a focus on profits.
NTES NetEase
$232.66

3.11 (1.35%)

12/19/18
UBSW
12/19/18
UPGRADE
UBSW
Buy
NetEase upgraded to Buy from Neutral at UBS
01/04/19
MACQ
01/04/19
UPGRADE
MACQ
Outperform
NetEase upgraded to Outperform from Neutral at Macquarie
01/14/19
LEHM
01/14/19
UPGRADE
Target $300
LEHM
Overweight
NetEase upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Gregory Zhao upgraded NetEase to Overweight and raised his price target for the shares to $300 from $270. The analyst sees Diablo Immortal, a game co-developed with Blizzard, being a revenue driver when launched in the second half of 2019. Further, he sees the China gaming sector outperforming amid an economic downturn.
01/14/19
BERN
01/14/19
INITIATION
Target $240
BERN
Market Perform
NetEase assumed with a Market Perform at Bernstein
Bernstein analyst David Dai assumed coverage on NetEase with a Market Perform and $240 price target.
LOPE Grand Canyon
$97.13

0.18 (0.19%)

11/09/18
BRRR
11/09/18
NO CHANGE
Target $150
BRRR
Outperform
Barrington says buy Grand Canyon on selloff, ups target to $150
Barrington analyst Alexander Paris raised his price target for Grand Canyon Education to $150 from $135 after the company's Q3 results last night topped expectations. The analyst attributes the pullback in the shares today to some confusion over guidance and recommends using the selloff as a buying opportunity. With the completion of the Grand Canyon Education sale and conversion, "significant incremental value" could be unlocked for shareholders as revenue growth is enhanced through additional university contracts and margins trend higher, Paris tells investors in a post-earnings research note. He keeps an Outperform rating on the shares. Grand Canyon in morning trading is down 9%, or $12.13, to $117.22.
12/18/18
BRRR
12/18/18
NO CHANGE
BRRR
Barrington views Grand Canyon acquisition of Orbis as 'attractive'
Barrington analyst Alexander Paris, Jr. reiterated an Outperform rating and $150 price target on Grand Canyon Education after the company announced it has entered into a definitive agreement to acquire Orbis Education Services for $362.5M in cash, an acquisition the analyst views as "atttractive." The analyst noted that Orbis is expected to generate 2018 revenue of $62M with EBITDA expected to be approximately breakeven.
01/15/19
BMOC
01/15/19
NO CHANGE
Target $117
BMOC
Outperform
Grand Canyon price target raised to $117 from $106 at BMO Capital
BMO Capital analyst Jeffrey Silber raised his price target on Grand Canyon to $117 and kept his Outperform rating on its shares. The analyst says the company is achieving "solid enrollment growth" and has also reached a "near inflection point for free cash flow growth". Silber adds that the recent discussions on "not-for-profit conversion could unlock value and reduce sector risk."
01/28/19
PIPR
01/28/19
NO CHANGE
Target $135
PIPR
Overweight
Grand Canyon may be range-bound over next 6-12 months, says Piper Jaffray
Piper Jaffray analyst Peter Appert lowered his price target for Grand Canyon Education to $135 from $140 while keeping an Overweight rating on the name. While the company's transition to an online program management business model creates near-term "noise" in earnings, the "New" Grand Canyon is well positioned to sustain long-term low-to-mid teens earnings growth, Appert tells investors in a research note. The analyst says that although slower near-term growth may keep the stock in the trading range over the next 6-12 months, he still views Grand Canyon as one of the most interesting long-term growth stories in the education sector.
SNPS Synopsys
$102.98

1.08 (1.06%)

12/06/18
12/06/18
UPGRADE
Target $110

Buy
Synopsys upgraded to Buy after 'ultra conservative' FY19 guidance at Benchmark
As previously reported, Benchmark analyst Gary Mobley upgraded Synopsys to Buy from Hold after the company reported slightly better than expected Q4 results and in-line FY19 guidance. He cites the recent share price decline ahead of the report, what he sees as a "high likelihood" that Synopsys will continue to experience high-single-digit percentage organic revenue growth and management's renewed focus to drive operating margins higher. Mobley, who also contends that management's FY19 revenue guidance will "prove ultra conservative," set a $110 price target on Synopsys shares.
12/06/18
NEED
12/06/18
NO CHANGE
Target $115
NEED
Buy
Synopsys price target raised to $115 from $105 at Needham
Needham analyst Richard Valera raised his price target on Synopsys to $115 and kept his Buy rating after its "solid" Q4 results and in-line initial FY19 guidance. The analyst points to "healthy design-driven demand for its tools despite macro turbulence" along with a raise by the company's "historically conservative management" for its long-term earnings growth from high single digit % to double-digits and a long-term revenue growth target of high single digits. Valera adds that the new targets are "supported by a healthier long term outlook for core Electronic Design Automation segment, as well as momentum and critical mass in the company's IP and SI businesses."
12/06/18
12/06/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Activision Blizzard (ATVI) upgraded to Overweight from Neutral at JPMorgan with analyst Alexia Quadrani saying the stock is down 45% from an all-time high in early October, and now trades at 16.5 times forward consensus earnings, compared to 25.5 times and 23.0 times on average over the prior one and three year periods. 2. Bristol-Myers (BMY) upgraded to Outperform from Market Perform at BMO Capital with analyst Alex Arfaei saying the risk-reward on the stock at current price "seems attractive." 3. Hostess Brands (TWNK) upgraded to Overweight from Neutral at JPMorgan analyst Ken Goldman saying by this time next year, today's two major headwinds - lost business with Walmart (WMT) and the "EBITDA-hemorrhaging" Cloverhill acquisition - will be lapped and potentially become tailwinds. 4. Spirit Airlines (SAVE) upgraded to Outperform from Neutral at with analyst Jose Caiado De Sousa saying after a "massive" Q4 unit revenue guidance boost last week, the analyst sees further upside in the equity into H1 of 2019, with expected continued momentum in non-ticket revenue production amid a lower oil environment and a benign competitive backdrop. 5. Synopsys (SNPS) upgraded to Buy from Hold at Benchmark with analyst Gary Mobley citing slightly better than expected Q4 results and in-line FY19 guidance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/08/19
KEYB
01/08/19
NO CHANGE
KEYB
Microsoft, Salesforce among top Software stocks to own in 2019, says KeyBanc
KeyBanc analyst Brent Bracelin notes that despite challenging market conditions during Q4, the 45 software applications in his coverage universe outperformed the broader market by a wide margin. While industry conditions for application software appear more volatile entering 2019, the analyst sees a favorable backdrop for modern cloud-based applications with recurring subscription-based revenue models and continues to favor growth over value. His top software application stocks to own for 2019 include Microsoft (MSFT), Synopsys (SNPS), PTC (PTC), RealPage (RP), Talend (TLND), Salesforce (CRM), Shopify (SHOP), Twilio (TWLO), Avalara (AVLR).
ET Energy Transfer LP
$15.51

-0.13 (-0.83%)

11/29/18
SBSH
11/29/18
INITIATION
SBSH
Buy
Energy Transfer LP initiated with a Buy at Citi
Citi analyst Timm Schneider started Energy Transfer LP with a Buy rating and $19 price target.
11/29/18
11/29/18
INITIATION

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pluralsight (PS) initiated with an Outperform at Baird. 2. Expedia (EXPE) initiated with a Market Perform at Telsey Advisory. 3. Energy Transfer LP (ET) initiated with a Buy at Citi. 4. Skyline (SKY) initiated with a Neutral at Credit Suisse. 5. CBS (CBS) and Viacom (VIAB, VIA) were reinstated with a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/18/18
MSCO
12/18/18
NO CHANGE
MSCO
Morgan Stanley upgrades Midstream sector view to Attractive
Morgan Stanley analyst Tom Abrams upgraded his view on the Midstream Energy MLPs and Diversified Natural Gas sector to Attractive, stating that he expects a year of better midstream performance given an attractive fundamental outlook for production volumes as projects move into service. He also sees the industry's "quality" as improving, with simpler structures, improved governance and better and improving balance sheets, Abrams tells investors. With all else equal, he prefers names such as Energy Transfer (ET) and Williams (WMB), which he says have less structural overhang, attractive fee-based growth and improving balance sheets. Abrams also identifies Kinder Morgan (KMI) and Plains All American (PAA) as stocks in the sector that have catalysts expected in 2019.
02/05/19
EVER
02/05/19
INITIATION
Target $18
EVER
Outperform
Energy Transfer LP initiated with an Outperform at Evercore ISI
Evercore ISI analyst Durgesh Chopra initiated Energy Transfer LP (ET) with an Outperform and named it a Top Pick with a $18 price. Chopra said Energy Transfer is one of the most diversified MLP and Pipeline companies with significant exposure to all growth basins, and the merger with Energy Transfer Operating (ETP) removes IDRs and lowers the cost of capital of the combined entity, removing an overhang.
CAKE Cheesecake Factory
$46.42

-0.07 (-0.15%)

12/19/18
MAXM
12/19/18
UPGRADE
MAXM
Buy
Cheesecake Factory upgraded to Buy from Hold at Maxim
Maxim analyst Stephen Anderson upgraded Cheesecake Factory to Buy from Hold.
01/08/19
RAJA
01/08/19
UPGRADE
RAJA
Outperform
Cheesecake Factory upgraded to Outperform from Market Perform at Raymond James
01/08/19
RAJA
01/08/19
UPGRADE
Target $50
RAJA
Outperform
Cheesecake Factory upgraded to Outperform, concerns overdone, says Raymond James
As previously reported, Raymond James upgraded Cheesecake Factory to Outperform from Market Perform and established a $50 price target. Analyst Brian Vaccaro raised Cheesecake's Q4 earnings estimate to 63c from 61c to reflect a comp of 1.5%, versus 1% prior, due to better than expected industry sales. The analyst believes sentiment is overly negative and that initial 2019 earnings guidance could be a positive catalysts for shares into the Q4 earnings season.
01/08/19
01/08/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Voya Financial (VOYA) upgraded to Buy from Neutral at Goldman Sachs analyst Alex Scott saying the company is well positioned to manage through the pullback in equity markets and still hit its targets of 10%-plus earnings growth. 2. Cheesecake Factory (CAKE) upgraded to Outperform from Market Perform at Raymond James with analyst Brian Vaccaro citing better than expected industry sales. 3. Union Pacific (UNP) upgraded to Outperform from Market Perform at Cowen, to Outperform from Sector Perform at RBC Capital and Scotiabank, and to Buy from Neutral at Seaport Global. 4. Monster Beverage (MNST) upgraded to Buy from Hold at SunTrust with analyst William Chappell saying after the recent declines in input costs and the "successful U.S. pricing actions," consensus expectations for the stock are too low, while the concerns over its partnership with Coca-Cola (KO) and challenges around growth in China are "overblown." 5. Molina Healthcare (MOH) upgraded to Overweight from Neutral at both JPMorgan and MUFG. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NE Noble Corp.
$3.32

0.17 (5.40%)

12/20/18
12/20/18
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Macerich (MAC) downgraded to Sector Weight from Overweight at KeyBanc. 2. Eventbrite (EB) downgraded to Hold from Buy at Stifel with analyst Scott Devitt citing valuation. 3. HSBC (HSBC) downgraded to Sell from Hold at Edward Jones. 4. Noble Corp (NE) and Ensco (ESV) were downgraded to Hold from Buy at Societe Generale. 5. Greif (GEF) downgraded to Underperform from Outperform at BMO Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/28/18
WELS
12/28/18
NO CHANGE
WELS
Wells sees 'rocky times ahead' for Oil Services and Equipment market
Emerging data points suggest "rocky times ahead" for the North American Oil Services and Equipment market in early 2019, Wells Fargo analyst Judson Bailey tells investors in a research note. As oil prices and macro conditions have weakened to end 2018, a number of recent conversations suggest a "quickly deteriorating" outlook for exploration and production budgets, activity levels and pricing over the first few months of 2019, adds the analyst. He believes the case for "much needed consolidation" across the U.S. oilfield services landscape "has never been greater."
01/16/19
SOCO
01/16/19
DOWNGRADE
SOCO
Equalweight
Noble Corp. downgraded to Equalweight from Overweight at Capital One
01/28/19
PART
01/28/19
UPGRADE
PART
Buy
Noble Corp. upgraded to Buy from Hold at Pareto
FL Foot Locker
$60.00

0.12 (0.20%)

01/09/19
01/09/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Buy from Hold at HSBC. 2. Bank of America (BAC) upgraded to Buy from Hold at Edward Jones and to Buy from Neutral at UBS. 3. Wendy's (WEN) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Bittner saying his work reveals an "intriguing setup" as Street's earnings and free cash flow estimates through 2020 have reset to levels that create an improved scenario for meets or beats, same-store sales appear to have drivers to accelerate into 2019 against conservative sell-side forecasts of sub-2% perpetually, new international strategy could unlock faster-than-expected long-term unit growth, and valuation at about 8% free cash flow yield implies very attractive upside/downside case against a highly stable financial model. 4. Akamai (AKAM) upgraded to Overweight from Sector Weight at KeyBanc with analyst Brandon Nispel saying his data tracker suggests upside to Q4 revenue, decreasing the risk to a Q1 and 2019 guide below expectations. 5. Foot Locker (FL) upgraded to Outperform from Neutral at Baird with analyst Jonathan Komp citing its relative valuation and strong backward looking indicators providing reason for optimism. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/25/19
JEFF
01/25/19
NO CHANGE
JEFF
Under Armour discounting down for tenth straight month, says Jefferies
Jefferies analyst Randal Konik says his firm's January webscrapes illustrate that Under Armour's (UAA) percentage of product on discount is down for the tenth month in a row year-over-year, while Adidas's (ADDYY) percentage is up for the eleventh month in a row. Further, Visits to Finish Line (FINL), Foot Locker (FL), and Under Armour websites reveal the HOVR, Project Rock, and Curry 6 are sold out in several sizes, indicating strong demand, Konik tells investors in a research note. He also believes that Nike (NKE) continues to dominate Adidas in running in the U.S.
01/25/19
JEFF
01/25/19
NO CHANGE
Target $67
JEFF
Buy
Foot Locker price target raised to $67 from $62 at Jefferies
Jefferies analyst Janine Stichter raised her price target for Foot Locker to $67 to reflect increased conviction that the company's business continues to gain momentum. Data the analyst looks at point to a Nike (NKE) resurgence in North America, "rising heat" around basketball and Jordans, a "healthy" innovation pipeline, and "controlled" promotions. The analyst still sees opportunity in Foot Locker shares despite the recent rally and keeps a Buy rating on the name.
02/08/19
BARD
02/08/19
NO CHANGE
Target $65
BARD
Outperform
Foot Locker's latest investment could be 'greatest yet,' says Baird
Baird analyst Jonathan Komp noted Foot Locker announced plans to invest $100M in 1661, a leading sneaker resale platform. The analyst said the move demonstrates the company's more aggressive push to engage with leading digital-first brands and companies. He said it provides an attractive means to participate in the secondary sneaker market, which he believes the company has long desired. Komp reiterated his Outperform rating and $65 price target on Foot Locker shares.
CBLK Carbon Black
$16.47

0.13 (0.80%)

07/13/18
SUSQ
07/13/18
INITIATION
Target $27
SUSQ
Neutral
Carbon Black initiated with a Neutral at Susquehanna
Susquehanna analyst Anne Meisner initiated Carbon Black with a Neutral and $27 price target.
10/29/18
JPMS
10/29/18
NO CHANGE
JPMS
JPMorgan lists potential Software takeover targets after Red Hat deal
The volume of acquisitions in Software appears to be picking up with over 70 transactions announced year-to-date including last night's Red Hat (RHT) takeover by IBM (IBM), JPMorgan analyst Sterling Auty tells investors in a research note. The analyst puts the deals announced this year into three buckets: strategic, where the acquirer looks to gain a strong foothold in a new segment, vertical acquiring companies, and valuation, with acquirers going after assets with discounted valuations. Auty sees number of companies fitting those same characteristics across his coverage universe. In the strategic category, the analyst sees Okta (OKTA), Palo Alto Networks (PANW), ServiceNow (NOW), RingCentral (RNG), Aspen Technology (AZPN) and DocuSign (DOCU) as potential acquisition targets. In the vertical industry exposure category, Auty lists Guidewire (GWRE), Veeva (VEEV), Medidata (MDSO), Ellie Mae (ELLI) and Q2 Holdings (QTWO) as potential targets. And in the attractive valuation bucket, the analyst sees FireEye (FEYE), Carbon Black (CBLK), Secureworks (SCWX), Akamai (AKAM) and LogMeln (LOGM) as potential candidates to get acquired.
01/28/19
RAJA
01/28/19
UPGRADE
Target $24
RAJA
Strong Buy
Carbon Black upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Michael Turits upgraded Carbon Black to Strong Buy with a price target of $24.
01/29/19
RAJA
01/29/19
UPGRADE
Target $24
RAJA
Strong Buy
Carbon Black upgraded to Strong Buy, risk/reward favorable, say Raymond James
As previously reported, Raymond James upgraded Carbon Black to Strong Buy from Outperform and maintained a $24 price target. Analyst Michael Turits said Carbon Black is an under-appreciated growth story that trades at a discount. Turtis continues to be positive on the demand environment for Next Generation Endpoint demand with security spending diversifying from core firewall toward areas including next generation endpoint, as well as Identity, cloud security, and security analytics, and next gen vendors taking market share of legacy AV vendors like Symantec and McAfee.
SPTN SpartanNash
$21.98

-0.25 (-1.12%)

11/09/18
BMOC
11/09/18
DOWNGRADE
BMOC
Market Perform
SpartanNash downgraded to Market Perform from Outperform at BMO Capital
11/09/18
BMOC
11/09/18
DOWNGRADE
Target $23
BMOC
Market Perform
SpartanNash cut to Market Perform at BMO Capital on declining profitability
As reported earlier, BMO Capital analyst Kelly Bania downgraded SpartanNash to Market Perform from Outperform and kept her price target at $23. The analyst notes that its progress and profitability continue to deteriorate in spite of its efforts to invest about 50% of its tax reform savings in wages and other areas. Bania further states that the risk-reward on the shares has turned more balanced, adding that it is now more "difficult to argue that valuation should go higher now that expectations are higher than several months ago."
11/15/18
NRCS
11/15/18
UPGRADE
NRCS
Buy
SpartanNash upgraded to Buy from Neutral at Northcoast
01/10/19
RBCM
01/10/19
INITIATION
Target $25
RBCM
Outperform
SpartanNash initiated with an Outperform at RBC Capital
RBC Capital analyst Bill Kirk initiated SpartanNash (SPTN) with an Outperform rating and a price target of $25, citing the "volume opportunity" from the integration of United Natural Foods (UNFI) with Supervalu (SVU). The analyst says that the deal should allow SpartanNash market share performance in Food Distribution to improve. Kirk further contends that improvement in food PPI data, which turned positive for the first time in 7 months, is not reflected in the current consensus for SpartanNash, while the headwinds related to freight costs are expected to ease.
VIPS Vipshop
$7.30

0.35 (5.04%)

11/02/18
OTRG
11/02/18
NO CHANGE
OTRG
Vipshop's Q3 online sales decelerate, says OTR Global
Pre-open, OTR Global said checks indicate Vipshop's Q3 sales trends declerated due to slowing traffic growth, a new pricing strategy, and increased competition. Further, the platform's partnership with JD.com (JD) and WeChat contributed little, the firm's analyst wrote in a note to investors.
01/23/19
KEYB
01/23/19
UPGRADE
KEYB
Overweight
Vipshop upgraded to Overweight from Sector Weight at KeyBanc
01/23/19
01/23/19
UPGRADE
Target $10

Overweight
Vipshop upgraded to Overweight at KeyBanc on improving fundamentals
As previously reported, KeyBanc analyst Hans Chung upgraded Vipshop to Overweight from Sector Weight, with a $10 price target. The analyst notes that sales turnovers have improved driven by a streamlined focus on the apparel category, discounted products in merchandising, and straightforward promotions via pricing discount, mix shift toward apparel should help improve gross margin, and deteriorating inventory level in the apparel industry since 2H18 should be a favorable trend for the company as he believes Vipshop's strength in merchandising and brand name for off-price retail will benefit itself in the destocking cycle.
02/19/19
BOFA
02/19/19
DOWNGRADE
Target $8.2
BOFA
Neutral
Vipshop downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Eddie Leung downgraded Vipshop to Neutral with a price target of $8.20. Decelerating online retail sales in China poses risks to the company's growth, Leung tells investors in a research note. The analyst sees less upside in Vipshop shares amid the macroeconomic uncertainty and following the recent rebound in the stock.
FLS Flowserve
$47.75

0.485 (1.03%)

12/18/18
MSCO
12/18/18
DOWNGRADE
MSCO
Underweight
Flowserve downgraded to Underweight from Equal Weight at Morgan Stanley
12/18/18
12/18/18
DOWNGRADE
Target $38

Underweight
Flowserve cut to Underweight on lack of turnaround conviction at Morgan Stanley
As previously reported, Morgan Stanley analyst Joshua Pokrzywinski downgraded Flowserve to Underweight from Equal Weight, stating that he came away from the company's analyst meeting last week with less conviction in the timing of a turnaround. He significantly reduced his target multiple after reassessing the company's potential future earning power. Management has called 2019 a "productivity" year, not a "restructuring" year, but the path to margin targets seems to require a more aggressive move around factory consolidation, closing QRCs or dramatically higher backlog margins, Pokrzywinski tells investors. He lowered his price target on Flowserve shares to $38 from $51.
12/18/18
12/18/18
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Philip Morris (PM) downgraded to Underperform from Neutral at Credit Suisse with analyst Alan Erskine saying after conducting a survey of next-generation products users in Japan, the U.S. and the U.K., he believes slower progress in the take-up of heated tobacco products and weaker combustible organic growth will challenge the high-single-digit earnings growth models of Philip Morris and British American Tobacco (BTI). 2. Wabco (WBC) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Courtney Yakavonis saying she is losing conviction that Wabco can return to its "normal" margin and outgrowth framework in FY19, citing rolling global truck markets, recent underperformance in core outgrowth, and sustained margin risks as limiting factors to the previously premium multiple. 3. Kansas City Southern (KSU) and Schneider National (SNDR) were downgraded to Neutral from Overweight at JPMorgan. 4. Illinois Tool Works (ITW) and Flowserve (FLS) were downgraded to Underweight from Equal Weight at Morgan Stanley, while Hubbell (HUBB) was downgraded to Equal Weight from Overweight at Morgan Stanley. 5. Worldpay (WP) downgraded to Outperform from Top Pick at RBC Capital with analyst Daniel Perlin saying while the company trades in line with its peers on a relative price-to-earnings basis, its shares remain attractive given the "conservative" expectations for synergy targets. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/03/19
FBCO
01/03/19
NO CHANGE
Target $42
FBCO
Neutral
Flowserve price target lowered to $42 from $48 at Credit Suisse
Credit Suisse analyst John Walsh lowered his price target for Flowserve to $42 from $48 to reflect a 20bps reduction in global industrial production expectations, a 200bps reduction in energy capex driven by reduced E&P spending, and current FX rates. The analyst reiterates a Neutral rating on the shares.
EVTC Evertec
$30.65

0.3 (0.99%)

06/15/18
RAJA
06/15/18
INITIATION
RAJA
Market Perform
Evertec initiated with a Market Perform at Raymond James
Raymond James analyst John Davis initiated Evertec with a Market Perform citing significant year-to-date outperformance and said shares are relatively balanced at current levels.
07/19/18
MSCO
07/19/18
NO CHANGE
MSCO
Morgan Stanley upgrades Payments and Processing industry to Attractive
Morgan Stanley analyst James Faucette upgraded his view of the Payments and Processing industry to Attractive, citing the firm's U.S. Strategy Team's call for rotation out of Technology and his view that Payments will be seen as an attractive option for investors looking to become more defensive. Investors underappreciate the resilience of consumer spending and Faucette sees the potential for his Payments coverage market-cap weighted earnings growth to accelerate organically to 15% over 2018-2020 from 11% growth over the last three years, he tells investors. In the group, the firm has Overweight ratings on Visa (V), MasterCard (MA), PayPal (PYPL), GreenSky (GSKY), Worldpay (WP) and FleetCor (FLT). Morgan Stanley has Underweight ratings on Western Union (WU) and On Deck Capital (ONDK), having downgraded On Deck this morning.
10/31/18
RAJA
10/31/18
UPGRADE
RAJA
Outperform
Evertec upgraded to Outperform from Market Perform at Raymond James
12/06/18
KBWI
12/06/18
INITIATION
KBWI
Outperform
Evertec initiated with an Outperform at Keefe Bruyette
Keefe Bruyette analyst Sanjay Sakhrani started Evertec with an Outperform rating.
CONE CyrusOne
$57.19

-0.46 (-0.80%)

11/01/18
COWN
11/01/18
NO CHANGE
Target $67
COWN
Outperform
CyrusOne price target lowered to $67 from $79 at Cowen
Cowen analyst Colby Synesael lowered his price target on CyrusOne to $67 from $79 following disappointing results. The analyst feels with current valuation at a trough, downside is limited. Synesael reiterated his Buy rating on CyrusOne shares.
12/17/18
MSCO
12/17/18
NO CHANGE
MSCO
North American REIT sector upgraded to In-Line at Morgan Stanley
Morgan Stanley analysts led by Richard Hill upgraded their sector view for North American REITs to In-Line from Cautious, noting that REIT growth is stabilizing and more appropriately priced, the setup for the sector relative to the broader market is favorable and the defensive characteristics of the group in a slowing economy. Calling the sector upgrade a "relative, not an absolute call," the analyst team identified CyrusOne (CONE), Essex Property Trust (ESS), Gaming and Leisure Properties (GLPI), Hudson Pacific (HPP), Prologis (PLD), Regency Centers (REG), SBA Communications (SBAC) and Store Capital (STOR) as their top picks.
01/02/19
BOFA
01/02/19
DOWNGRADE
BOFA
Neutral
CyrusOne downgraded to Neutral from Buy at BofA/Merrill
01/02/19
01/02/19
DOWNGRADE

Neutral
CyrusOne downgraded to Neutral on funding pressures at BofA/Merrill
As previously reported, BofA/Merrill downgraded CyrusOne to Neutral from Buy and lowered its price target to $55 from $65. Analyst Michael Funk said the projected $600M equity raise based on projected development spending may weigh on shares and notes the labor market is tightening and raw material costs are rising. Further, Funk views Street FFO/share and AFFO/share estimates as too high.
XEC Cimarex Energy
$76.38

1.3 (1.73%)

01/29/19
MZHO
01/29/19
INITIATION
MZHO
Neutral
Cimarex Energy initiated with a Neutral at Mizuho
Mizuho analyst Paul Sankey initiated Cimarex Energy with a Neutral and $80 price target.
01/29/19
01/29/19
INITIATION

Mizuho initiates seven 'exciting' E&P stocks
Mizuho analyst Paul Sankey expanded his coverage of the E&P, or exploration and production, sector with the initiation of seven U.S.-focused, liquids-weighted E&Ps. Sankey initiated Concho Resources (CXO), Continental Resources (CLR), and Diamondback Energy (FANG) with Buy ratings, and Cimarex Energy Company (XEC), Encana Corporation (ECA), Parsley Energy (PE), and WPX Energy (WPX) with Neutral ratings. The analyst views each of these names as quality operators at varying stages in the transition to "Renaissance E&P." He believes "sustainable cash return growth is the key to making E&Ps competitive, not just relative to their history, but to the broader market," and sees his three Buy-rated names as the furthest along this process.
02/08/19
SUSQ
02/08/19
UPGRADE
SUSQ
Positive
Cimarex Energy upgraded to Positive from Neutral at Susquehanna
02/08/19
SUSQ
02/08/19
UPGRADE
Target $88
SUSQ
Positive
Cimarex Energy upgraded to Positive, price target raised to $88 at Susquehanna
As reported previously, Susquehanna analyst Biju Perincheril upgraded Cimarex Energy to Positive from Neutral. The analyst believes its capital efficiency is set to improve as an extended period of Permian spacing tests, which negatively impacted well productivity, is largely behind the company. This, coupled with more oil-well growth from REN assets, provides a visible path for free-cash-flow generations, said Perincheril, who raised his price target to $88 from $74 on Cimarex shares.
XPER Xperi
$23.18

0.36 (1.58%)

11/08/18
CHLM
11/08/18
NO CHANGE
Target $20
CHLM
Buy
Xperi price target lowered to $20 from $25 at Craig-Hallum
Craig-Hallum analyst Richard Shannon lowered his price target for Xperi to $20 from $25 following quarterly results. The analyst reiterates a Buy rating on the shares.
12/10/18
BNCH
12/10/18
NO CHANGE
Target $35
BNCH
Buy
Xperi settlement removes Samsung uncertainty, says Benchmark
After Xperi (XPER) announced a patent license agreement with Samsung (SSNLF) that it said settles all outstanding legal matters between the parties, Benchmark analyst Gary Mobley said he believes the pact "removes nearly all of the uncertainty that has plagued the shares during the past two years." He raised his price target on Xperi shares to $35 from $25 to account for his higher FY19 estimates and keeps an Buy rating on the stock, which he still views as undervalued.
12/11/18
RILY
12/11/18
NO CHANGE
Target $30
RILY
Buy
Xperi price target raised to $30 from $23 at B. Riley FBR
B. Riley FBR analyst Eric Wold raised his price target for Xperi to $30 after the company agreed to a settlement/dismissal of all litigation against Samsung in exchange for new patent license agreement. Along with Broadcom (AVGO) license,the Samsung news helps validate Xperi management's pivot away from outsourced semiconductor and test services providers to manufacturers, Wold tells investors in a research note. He now has increased confidence in the company's upcoming major license renewals and its ability to reduce litigation spend in 2019. The analyst keeps a Buy rating on Xperi.
12/11/18
CHLM
12/11/18
NO CHANGE
Target $28
CHLM
Buy
Xperi price target raised to $28 from $20 at Craig-Hallum
Craig-Hallum analyst Richard Shannon raised his price target for Xperi to $28 from $20 (XPER), while reiterating a Buy rating on the shares. The analyst notes that the the company's Samsung (SSNLF) settlement is a critical event in its history as it shows that its portfolio has substantial ongoing value, and that Xperi is willing to be patient to find a fair settlement.
SM SM Energy
$19.70

0.61 (3.20%)

12/10/18
GHSC
12/10/18
UPGRADE
Target $34
GHSC
Buy
SM Energy upgraded to Buy from Neutral at Seaport Global
Seaport Global analyst Mike Kelly upgraded SM Energy to Buy from Neutral and raised its price target to $34 from $29. Kelly views valuation as attractive following the 40% drop in shares since October and rerated his model higher to account for Howard County strong results.
12/14/18
TUDR
12/14/18
DOWNGRADE
TUDR
Hold
SM Energy downgraded to Hold from Buy at Tudor Pickering
12/20/18
SOCO
12/20/18
DOWNGRADE
SOCO
Equalweight
SM Energy downgraded to Equalweight from Overweight at Capital One
01/16/19
LEHM
01/16/19
INITIATION
Target $27
LEHM
Overweight
SM Energy initiated with an Overweight at Barclays
Barclays analyst Jeanine Wai started SM Energy with an Overweight rating and $27 price target. The analyst sees the company being cash flow positive in 2020 without deviating much for its current seven active rigs.
A Agilent
$78.56

1.08 (1.39%)

11/20/18
JPMS
11/20/18
NO CHANGE
Target $80
JPMS
Overweight
Agilent reported 'exceedingly strong quarter,' says JPMorgan
JPMorgan analyst Tycho Peterson says Agilent Technologies reported an "exceedingly strong quarter," with core growth of 9% "well above guidance and elevated expectations." The analyst continues to like the story and maintain an Overweight rating on the shares with an $80 price target. Heading into fiscal 2019 and beyond, Peterson continues to see "multiple drivers" to accelerate growth, including the Intuvo/Ultivo product cycles and accelerating momentum in biopharma.
01/02/19
NEED
01/02/19
INITIATION
Target $77
NEED
Buy
Agilent initiated with a Buy at Needham
Needham analyst Stephen Unger started Agilent Technologies with a Buy rating and $77 price target. The analyst sees "significant potential" for ongoing earnings upside as the company leverages its "expanding portfolio" of advanced technologies.
01/03/19
BOFA
01/03/19
NO CHANGE
Target $78
BOFA
Buy
Agilent initial FY19 guidance looks conservative, says BofA/Merrill
BofA/Merrill Derik de Bruin kept his Buy rating and his $78 price target on Agilent but designated the stock as his top pick for 2019 as part of his broader research note on Life Sciences & Diagnostic Tools. The analyst notes that while the Life Science Tool sector valuations remain at a premium relative to the S&P500 and most other healthcare sub-sectors, the gap has narrowed as organic growth slowed to just over 6%. de Bruin sees sector growth moderating further to 5% because of tough comps in 2019, but he is also positive on the industry's long-term positioning to "to reduce cyclical exposure and increase the level of recurring revenues." The analyst is especially positive on Agilent, where valuations have compressed from 28-times to 20-times earnings because of its "higher than average exposure to chemical and energy customers, concerns over China and trade, and cheaper opportunities elsewhere in the sector", but he sees the company's portfolio becoming much less cyclical today.
02/12/19
DBAB
02/12/19
NO CHANGE
Target $85
DBAB
Buy
Agilent price target raised to $85 from $80 at Deutsche Bank
Deutsche Bank analyst Dan Leonard raised his price target for Agilent Technologies to $85 citing a roll-forward of his valuation methodology by one quarter. The analyst believes Agilent has more opportunities for growth, margin expansion, and capital deployment than peers. He keeps a Buy rating on the shares.
PI Impinj
$19.30

1.39 (7.76%)

09/13/18
PIPR
09/13/18
NO CHANGE
PIPR
Impinj price target raised to $31 from $26 at Piper Jaffray
Piper Jaffray analyst Troy Jensen reiterated an Overweight rating on Impinj shares and increased his price target to $31 from $26, citing impressive Q2 earnings results with revenues, margins, profitability and guidance all considerably above consensus estimates. Jensen believes Impinj is likely entering a stage with better execution and "the opportunity for more frequent upward revisions."
10/19/18
PIPR
10/19/18
NO CHANGE
PIPR
Piper Jaffray lists 'stocks to own' following tech sector sell-off
Piper Jaffray's tech analysts highlighted their "stocks to own" following the recent sell-off in the technology sector. The firm's top picks across each coverage universe include Amazon.com (AMZN), Broadcom (AVGO), Salesforce (CRM), Finisar (FNSR), Microchip (MCHP), Mellanox (MLNX), ServiceNow (NOW), Nutanix (NTNX), Proofpoint (PFPT), Impinj (PI), Take-Two (TTWO) and Twilio (TWLO).
10/30/18
PIPR
10/30/18
NO CHANGE
Target $31
PIPR
Overweight
Impinj growth will continue to reaccelerate, says Piper Jaffray
With last night's "record quarter," Impinj's issues from prior quarters are now behind the company and its growth will continue to reaccelerate going forward, Piper Jaffray analyst Troy Jensen tells investors in a research note. He believes the company's current strength is "fairly broad-based with strength in retail, airlines, health care, automotive and other verticals all showing positive momentum." The RAIN RFID market represents one of the better growth markets and Impinj is the best way to play the trend, says Jensen. He reiterates an Overweight rating on the shares with a $31 price target.
10/30/18
ADAM
10/30/18
NO CHANGE
Target $31
ADAM
Buy
Impinj relationships should lead to market penetration, says Canaccord
Canaccord analyst T. Michael Walkley noted Impinj reported solid Q3 results with revenues slightly above guidance and returning to year-over-year growth for the first time since Q3 2017. The analyst believes the industry will return to more normalized growth and with the company's relationships with leading retailers and healthcare providers, it is in a solid position to increase market penetration. Walkley reiterated his Buy rating and $31 price target on Impinj shares.
QEP QEP Resources
$8.19

-0.08 (-0.97%)

11/20/18
11/20/18
UPGRADE
Target $11

Neutral
QEP Resources upgraded to Neutral on valuation at Credit Suisse
As previously reported, Credit Suisse analyst Betty Jiang upgraded QEP Resources to Neutral from Underperform, with a $11 price target, as accretive Haynesville sale leaves residual pure-play Permian E&P trading at a large discount to peers. Although both Bakken and Haynesville deals came in at or below the low-end of her initial valuation range, QEP executed on both sales despite substantial market skepticism, Jiang contends.
11/29/18
COWN
11/29/18
INITIATION
Target $10
COWN
Market Perform
QEP Resources initiated with a Market Perform at Cowen
Cowen started QEP Resources with a Market Perform rating and $10 price target.
12/06/18
SPHN
12/06/18
INITIATION
Target $12
SPHN
Equal Weight
QEP Resources initiated with an Equal Weight at Stephens
Stephens analysts Gail Nicholson and Drew Lipke began coverage of the E&P sector with a positive outlook, starting QEP Resources with an Equal Weight rating and $12 price target.
12/20/18
SOCO
12/20/18
DOWNGRADE
SOCO
Equalweight
QEP Resources downgraded to Equalweight from Overweight at Capital One
NUVA NuVasive
$55.47

-1.81 (-3.16%)

02/11/19
ADAM
02/11/19
NO CHANGE
ADAM
Canaccord says sell NuVasive on deal speculation rally, buy Smith & Nephew
Canaccord Genuity analyst Kyle Rose advises investors in the near-term to sell NuVasive (NUVA) into the deal-related strength and add to positions in Smith & Nephew (SNN) on the acquisition speculation selloff. The analyst does not find a potential of NuVasive acquisition by Smith & Nephew "to be compelling." A deal could be disruptive to Smith & Nephew's turnaround in both commercial performance and investor sentiment, Rose told investors earlier in a research note. The analyst admits to being caught off guard by Friday's Financial Times report of deal talks. Not by the idea of M&A speculation, but rather the idea of Smith & Nephew "choosing to utilize nearly all of its acquisition bandwidth on a spine acquisition," says Rose. He believes the spine market "doesn't seem to check the right 'growth' boxes." Further, spine deals are "notoriously challenging" given the importance of the distributor/customer relationship and disruption caused in the commercial channels during integration, he adds. Should the talks progress, Rose believes it would take at least $60 per share, or a 21% premium to Friday's closing price, for NuVasive to seriously consider a deal. Share of NuVasive are up 15%, or $7.64, to $57.19 in midday trading while Smith & Nephew is down 4% to $38.43. From a long-term perspective, the analyst says he would maintain Buy ratings on both stocks should the deal were not to be ultimately consummated.
02/12/19
JEFF
02/12/19
DOWNGRADE
JEFF
Hold
NuVasive downgraded to Hold from Buy at Jefferies
02/12/19
JEFF
02/12/19
DOWNGRADE
Target $60
JEFF
Hold
Jefferies, skeptical of potential buyout, downgrades NuVasive to Hold
Jefferies analyst Raj Denhoy downgraded NuVasive (NUVA) to Hold from Buy and lowered his price target for the shares to $60 from $68. The analyst remains skeptical of a takeover by Smith & Nephew (SNN) happening, and even if it does, he does not see much opportunity for a bid above $60 per share. NuVasive closed yesterday up 13% to $56.12. And outside of a potential takeover, NuVasive's story is challenging amid slowing spine growth, Denhoy tells investors in a research note.
02/12/19
LSCM
02/12/19
NO CHANGE
Target $7
LSCM
Buy
Alphatec transformation on track despite share weakness, says Lake Street
Lake Street analyst Brooks O'Neil believes his fundamental thesis on Alphatec (ATEC) is playing out despite the recent weakness in the shares. CEO Pat Miles and his team are spine experienced and taking "significant steps" to strengthen the company's distributor relationships and to revitalize its product line, O'Neil tells investors in a research note. Initial feedback on new products has been very positive, says the analyst. He affirms his Buy rating on Alphatec with a $7 price target. Further, following reports of Smith & Nephew's (SNN) interest in NuVasive (NUVA), O'Neil says one of the larger players in the spine space "might take a run at" Alphatec should its transformation continue as he expects.
ICLR Icon
$145.61

0.28 (0.19%)

10/26/18
10/26/18
UPGRADE
Target $156

Outperform
Evercore ISI upgrades Icon to Outperform after M&A fears fail to materialize
As previously reported, Evercore ISI analyst Ross Muken upgraded Icon to Outperform from In Line, stating that his prior concerns of an uptick in biopharma M&A, notably among the company's largest customers, clearly hasn't played out. With that fear likely de-risked, he said he can turn back to fundamentals, "which are pretty awesome." CRO industry growth remains in the mid-single digits and he expects Icon to grow above this rate, Muken tells investors. However, he lowered his price target on Icon shares to $156 from $161.
12/14/18
GSCO
12/14/18
DOWNGRADE
GSCO
Buy
Icon downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Asad Haider removed Icon from the Conviction Buy List citing recent outperformance. Shares remain Buy rated with a $168 price target.
01/11/19
GSCO
01/11/19
UPGRADE
Target $151
GSCO
Conviction Buy
Iqvia upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Robert Jones added Iqvia Holdings (IQ) to his firm's Americas Conviction List while keeping a Buy rating on the shares. The analyst lowered his price target for the shares to $151 from $152. He sees "several drivers of upside" in 2019 against a "very healthy" industry backdrop. Iqvia's backlog growth along with an industry leading book-to-bill indicate its offering is resonating in the market, Jones tells investors in a research note. He believes the company's upcoming commentary accompanying 2019 guidance could serve as a potential catalyst for the shares. Jones is also positive on shares of Icon (ICLR).
01/25/19
MZHO
01/25/19
UPGRADE
Target $150
MZHO
Buy
Icon upgraded to Buy from Neutral at Mizuho
Mizuho analyst Ann Hynes upgraded Icon to Buy and raised her price target for the shares to $150 from $146. The recent volatility in the Contract Research Organization group provides a "nice entry point" into Icon shares, Hynes tells investors in a research note. She prefers Icon to the other CROs due to the "quality" of its earnings, "strong" cash conversion, and potential for earnings upside versus its peers.
NDSN Nordson
$138.81

-0.42 (-0.30%)

11/29/18
DADA
11/29/18
DOWNGRADE
DADA
Neutral
Nordson downgraded to Neutral from Buy at DA Davidson
11/29/18
DADA
11/29/18
DOWNGRADE
Target $125
DADA
Neutral
Nordson downgraded to Neutral at DA Davidson on China and trade concerns
As reported earlier, DA Davidson analyst Matt Summerville downgraded Nordson to Neutral from Buy and lowered his price target to $125 from $160 while also reducing his FY19 and FY20 EPS views by 40c to $6.20 and $6.95 respectively. The analyst believes that the current Street consensus for Nordson's Q1 and FY19 is too high because of the weaker macro environment in China - particularly in consumer electronics - as evidenced by its decline in consumer confidence since February. Summerville also points to the headwinds of trade and tariff related uncertainty as well as the adverse FX impact on the company that is expected to persist throughout FY19.
01/08/19
OPCO
01/08/19
UPGRADE
OPCO
Outperform
Nordson upgraded to Outperform from Perform at Oppenheimer
01/08/19
OPCO
01/08/19
UPGRADE
Target $140
OPCO
Outperform
Nordson upgraded to Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Christopher Glynn upgraded Nordson to Outperform from Perform, with a $140 price target. The analyst notes that the company has delivered organic growth for nine straight years through FY18, and guided FY19 for 3%-5% organic growth and 100bps-150 bps OM expansion. Organic growth was slightly negative over the prior three quarters and will certainly be so in FY1Q18 on a particularly onerous comparison, but that is all well known, he contends. While Glynn acknowledges that shares are not cheap in the current market, he expects about 110% structural free cash flow/NI long-term and 120% in FY19 on expected solid working capital execution versus historical, including some benefits from facilities consolidations at ADS.
SEDG SolarEdge
$41.48

-1.87 (-4.31%)

11/30/18
ROTH
11/30/18
NO CHANGE
Target $50
ROTH
Buy
SolarEdge price target cut to $50 from $60 at Roth Capital
After hosting meetings with SolarEdge's CFO, Ronen Faier, Roth Capital analyst Philip Shen lowered his price target to $50 from $60. In a research note to investors, Shen says investors were focused on Huawei, recent margin weakness due to warranty servicing, margin impact due to tariffs and manufacturing capacity inversion, and getting more details on the Kokam acquisition. Although Shen maintains a Buy given the company's near-term cash generation potential, he acknowledges the Huawei risk around the corner.
01/17/19
JMPS
01/17/19
DOWNGRADE
JMPS
Underperform
SolarEdge downgraded to Underperform from Market Perform at JMP Securities
01/17/19
01/17/19
DOWNGRADE
Target $31

Underperform
JMP downgrades SolarEdge to Underperform on valuation concerns
As previously reported, JMP Securities analyst Joseph Osha downgraded SolarEdge to Underperform from Market Perform on his view that it may be difficult for the stock to keep its current valuation given the likelihood he sees that EBITDA and earnings decline year-over-year in 2019. However, Osha also noted that his revised estimates are not far from consensus and he does not expect any surprises when the company reports its Q4 results. Osha set a $31 price target on SolarEdge shares.
02/12/19
BOFA
02/12/19
NO CHANGE
BOFA
First Solar, Canadian Solar likely to beat quarter estimates, says BofA/Merrill
BofA/Merrill analyst Brian Lee says that despite the strong year-to-date outperformance across the group, he would lean into solar stocks heading into Q4 earnings as he sees momentum likely to persist for stocks that can beat, namely First Solar (FLSR) and Canadian Solar (CSIQ). Fundamentally, the analyst expects a much more constructive tone from companies heading into 2019, and sees both companies as best positioned to beat given First Solar's better margins and Canadian Solar's project sales that consensus is not capturing. On the flipside, Lee reiterates a Sell rating on SolarEdge (SEDG), which he sees as having the highest idiosyncratic risk and lower estimates owing to recent M&A that appears both dilutive and a key investor focus point.
RBBN Ribbon Communications
$6.06

-0.08 (-1.30%)

03/12/18
WBLR
03/12/18
NO CHANGE
WBLR
Ribbon Communications selloff today a buying opportunity, says William Blair
William Blair analyst Dmitry Netis says today's "unexplained" selloff in shares of Ribbon Communications provides a buying opportunity. The analyst sees no fundamental issues with the Q4 results and attributes part of the pullback to the thin float. He keeps an Outperform rating on the shares.
08/01/18
COWN
08/01/18
UPGRADE
COWN
Market Perform
Ribbon Communications upgraded to Market Perform from Underperform at Cowen

TODAY'S FREE FLY STORIES

AKAM

Akamai

$90.95

-0.13 (-0.14%)

21:13
09/18/19
09/18
21:13
09/18/19
21:13
Downgrade
Akamai rating change  »

Akamai downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

DB

Deutsche Bank

$8.06

-0.125 (-1.53%)

20:32
09/18/19
09/18
20:32
09/18/19
20:32
Hot Stocks
Deutsche Bank lowers prime lending rate to 5.00% from 5.25% »

Deutsche Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRVB

Provention Bio

$9.70

0.33 (3.52%)

20:31
09/18/19
09/18
20:31
09/18/19
20:31
Syndicate
Provention Bio 5M share Spot Secondary priced at $8.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 19

    Sep

DRI

Darden

$127.40

1.31 (1.04%)

20:25
09/18/19
09/18
20:25
09/18/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

XGN

Exagen

$0.00

(0.00%)

19:48
09/18/19
09/18
19:48
09/18/19
19:48
Syndicate
Exagen 3.6M share IPO priced at $14.00 »

The deal priced at low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

PING

Ping Identity

$0.00

(0.00%)

19:35
09/18/19
09/18
19:35
09/18/19
19:35
Syndicate
Ping Identity 12.5M share IPO priced at $15.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

CBS

CBS

$43.38

0.08 (0.18%)

, T

AT&T

$36.77

-0.39 (-1.05%)

19:04
09/18/19
09/18
19:04
09/18/19
19:04
Periodicals
Viacom, CBS, WarnerMedia pull e-cigarette ads from networks, CNBC says »

CBS (CBS),…

CBS

CBS

$43.38

0.08 (0.18%)

T

AT&T

$36.77

-0.39 (-1.05%)

VIA

Viacom

$27.94

-0.06 (-0.21%)

VIAB

Viacom

$25.77

0.02 (0.08%)

BTI

British American Tobacco

$36.90

0.06 (0.16%)

MO

Altria Group

$40.84

-0.47 (-1.14%)

PM

Philip Morris

$71.58

-0.4 (-0.56%)

IMBBY

Imperial Brands

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Nov

CRON

Cronos Group

$10.96

-0.205 (-1.84%)

18:57
09/18/19
09/18
18:57
09/18/19
18:57
Hot Stocks
Cronos Group CEO: We focus on supply and the consumer »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$44.48

-0.02 (-0.04%)

, SVRA

Savara

$2.49

-0.14 (-5.32%)

18:46
09/18/19
09/18
18:46
09/18/19
18:46
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MLHR

Herman Miller

$44.48

-0.02 (-0.04%)

SVRA

Savara

$2.49

-0.14 (-5.32%)

CBPO

China Biologic

$103.19

0.37 (0.36%)

NCR

NCR Corp.

$33.62

0.77 (2.34%)

MSFT

Microsoft

$138.53

1.13 (0.82%)

TNDM

TNDM

X

U.S. Steel

$12.45

-0.51 (-3.94%)

PRVB

Provention Bio

$9.70

0.33 (3.52%)

PAA

Plains All American

$21.87

-0.315 (-1.42%)

COST

Costco

$292.47

0.96 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 23

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 21

    Oct

  • 22

    Oct

  • 27

    Oct

  • 05

    Nov

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

TECD

Tech Data

$103.32

-0.59 (-0.57%)

18:41
09/18/19
09/18
18:41
09/18/19
18:41
Hot Stocks
Tech Data CEO: We are confident in our company and where we are going »

Tech Data CEO Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$36.77

-0.39 (-1.05%)

, DISH

Dish

$35.58

0.3 (0.85%)

18:34
09/18/19
09/18
18:34
09/18/19
18:34
Periodicals
AT&T, Dish not in discussions over DirecTV deal, Reuters reports »

AT&T (T) and Dish…

T

AT&T

$36.77

-0.39 (-1.05%)

DISH

Dish

$35.58

0.3 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Oct

AGCO

Agco

$76.04

-0.16 (-0.21%)

18:30
09/18/19
09/18
18:30
09/18/19
18:30
Hot Stocks
Agco CEO: We are on schedule in the U.S. »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$14.63

-0.31 (-2.08%)

18:22
09/18/19
09/18
18:22
09/18/19
18:22
Periodicals
Petrobras raises gasoline, diesel prices in wake of Saudi attacks, Reuters says »

Petrobras has boosted the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$123.69

-0.28 (-0.23%)

18:01
09/18/19
09/18
18:01
09/18/19
18:01
Hot Stocks
Celanese increases Vinyl Acetate Monomer price in EMEA by EUR50/MT »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STI

SunTrust

$68.57

0.48 (0.70%)

18:00
09/18/19
09/18
18:00
09/18/19
18:00
Hot Stocks
SunTrust lowers prime lending rate to 5% from 5.25% »

Following the Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBS

Webster Financial

$48.84

0.43 (0.89%)

17:53
09/18/19
09/18
17:53
09/18/19
17:53
Hot Stocks
Webster Financial lowers prime lending rate to 5.0% from 5.25% 

Effective September 19.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 13

    Nov

HSBC

HSBC

$38.19

-0.1 (-0.26%)

17:52
09/18/19
09/18
17:52
09/18/19
17:52
Hot Stocks
HSBC decreases prime lending rate to 5% from 5.25% »

HSBC Bank USA and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

HES

Hess Corp.

$66.91

-0.92 (-1.36%)

17:50
09/18/19
09/18
17:50
09/18/19
17:50
Hot Stocks
Hess Corp. COO sells 17,750 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

CSCO

Cisco

$49.32

-0.1 (-0.20%)

, DDOG

Datadog

$0.00

(0.00%)

17:46
09/18/19
09/18
17:46
09/18/19
17:46
Periodicals
Cisco approached Datadog with $7B+ takeover bid, Bloomberg says »

Cisco (CSCO) approached…

CSCO

Cisco

$49.32

-0.1 (-0.20%)

DDOG

Datadog

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 13

    Nov

  • 19

    Sep

ASB

Associated Banc-Corp

$20.23

0.075 (0.37%)

17:46
09/18/19
09/18
17:46
09/18/19
17:46
Hot Stocks
Associated Banc-Corp lowers prime rate to 5.0% from 5.25% 

Effective September 19.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$140.69

-0.93 (-0.66%)

17:45
09/18/19
09/18
17:45
09/18/19
17:45
Hot Stocks
SPDR Gold Shares holdings rise to 883.60MT from 880.37MT »

This is the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$36.77

-0.39 (-1.05%)

, DISH

Dish

$35.58

0.3 (0.85%)

17:44
09/18/19
09/18
17:44
09/18/19
17:44
Periodicals
AT&T exploring options to part with DirecTV unit, WSJ says »

AT&T (T) is looking…

T

AT&T

$36.77

-0.39 (-1.05%)

DISH

Dish

$35.58

0.3 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Oct

CBPO

China Biologic

$103.19

0.37 (0.36%)

17:43
09/18/19
09/18
17:43
09/18/19
17:43
Hot Stocks
China Biologic up 7% after receiving 'going private' proposal for $120 per share »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$36.77

-0.39 (-1.05%)

, DISH

Dish

$35.58

0.3 (0.85%)

17:42
09/18/19
09/18
17:42
09/18/19
17:42
Hot Stocks
AT&T, Dish move higher after WSJ report that AT&T has explored DirecTV options »

Shares of both AT&T…

T

AT&T

$36.77

-0.39 (-1.05%)

DISH

Dish

$35.58

0.3 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Oct

GSK

GlaxoSmithKline

$41.06

-0.04 (-0.10%)

17:41
09/18/19
09/18
17:41
09/18/19
17:41
Periodicals
FDA panel recommends approval of GSK's nicotine oral spray, Reuters says »

An independent expert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 27

    Sep

  • 02

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.